Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

Dexamethasone 6Bortezomib 3pomalidomide 2ixazomib 2filanesib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Calcium Dobesilate 2milatuzumab 1Thalidomide 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Lenalidomide 1Gemcitabine 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Plasmacytoma × Bortezomib × Clear all
NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed
498 enrolled 15 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT00569868 2011-08-12

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

University of Arkansas

Phase NA Completed
11 enrolled 4 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡